FrancophonIA/ELRC3.0 huggingface dataset:
English: Co-administration of midazolam, a CYP3A4 substrate, with brentuximab vedotin did not alter the metabolism of midazolam; therefore brentuximab vedotin is not expected to alter the exposure to medicines that are metabolized by CYP3A4 enzymes.
Croatian: Istodobna primjena midazolama, supstrata CYP3A4, s brentuksimab vedotinom nije promijenila metabolizam midazolama, stoga se ne očekuje da će brentuksimab vedotin promijeniti izloženost lijekovima koje metaboliziraju enzimi CYP3A4.
English: Therefore, co-administration of brentuximab vedotin with strong CYP3A4 and P-gp inhibitors may increase the incidence of neutropenia.
Croatian: Stoga, istodobna primjena brentuksimab vedotina s jakim inhibitorima CYP3A4 i P-gp može povećati incidenciju neutropenije.
English: • Best response of PR or SD to most recent salvage therapy as determined by CT and/or PET scanning
Croatian: • Najbolji odgovor na posljednju terapiju spasa u obliku djelomične remisije ili stabilne bolesti prema nalazima CT i/ili PET snimanja
English: The range of DOR was 1.2+ months to 43+ months and the median follow-up time from first dose for patients who achieved objective response (OR) per IRF was 9.0 months.
Croatian: Raspon DOR iznosio je 1,2+ mjeseca do 43+ mjeseca, a medijan trajanja praćenja od prve doze za bolesnike koji su postigli objektivni odgovor (OR) prema IRF-u iznosio je 9,0 mjeseci.
English: The range of DOR was 0.1 months to 39.1+ months and the median follow-up time from first dose for patients who achieved objective response (OR) per IRF was 15.5 months.
Croatian: Raspon DOR iznosio je 0,1 mjesec do 39,1+ mjesec, a medijan trajanja praćenja od prve doze kod bolesnika koji su, prema IRF-u, postigli objektivni odgovor (OR) bio je 15,5 mjeseci.
English: Phase 1 of the study assessed the safety profile (see section 4.8), determined the paediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D),
Croatian: U fazi 1 ispitivanja ocijenjen je sigurnosni profil (vidjeti dio 4.8), utvrđena najveća podnošljiva doza (engl. maximum tolerated dose, MTD) za pedijatrijsku populaciju i/ili preporučena doza za fazu 2 (engl. recommended phase 2 dose, RP2D), te procijenjena farmakokinetika lijeka ADCETRIS (vidjeti dio 5.2).
English: The usual dose of Adcetris given in combination with other chemotherapy medicines is 1.2 mg/kg given every 2 weeks for 6 months.
Croatian: Uobičajena doza lijeka Adcetris kada se daje u kombinaciji s drugim kemoterapijskim lijekovima je 1,2 mg/kg svaka 2 tjedna tijekom 6 mjeseci.
English: Unstratified Hazard Ratio and p-value
Croatian: Nestratificirani omjer rizika i p-vrijednost
English: 1.44 vials
Croatian: 1.44 bočica
English: There were no formal drug-drug interaction studies with brentuximab vedotin and bleomycin(B).
Croatian: Formalna ispitivanja interakcije brentuksimab vedotina i bleomicina (B) nisu provedena.
English: In nonclinical studies, thymus depletion has been observed (see section 5.3).
Croatian: U nekliničkim ispitivanjima opažena je deplecija timusa (vidjeti dio 5.3).
English: The efficacy of retreatment in patients who had previously responded (CR or PR) to treatment with ADCETRIS was evaluated in a phase 2, open-label, multicenter trial.
Croatian: Djelotvornost ponovnog liječenja u bolesnika koji su prethodno postigli odgovor (CR ili PR) na liječenje lijekom ADCETRIS procijenjeno je u otvorenom multicentričnom ispitivanju faze 2.
English: No effect was observed in patients with mild or moderate renal impairment.
Croatian: Učinak nije uočen kod bolesnika s blagim ili umjerenim oštećenjem bubrega.
English: At the time of last evaluation, most of the patients (82-85%) who experienced peripheral neuropathy had resolution or improvement of their peripheral neuropathy symptoms.
Croatian: U vrijeme zadnje procjene, u većine bolesnika (82-85%) koji su razvili perifernu neuropatiju, simptomi periferne neuropatije su se povukli ili poboljšali.
English: Patients should be closely monitored for new or worsening abdominal pain, which may be suggestive of acute pancreatitis.
Croatian: Bolesnike treba pozorno pratiti zbog moguće pojave ili pogoršanja bola u abdomenu, što može upućivati na akutni pankreatitis.
English: Use of ADCETRIS in combination with chemotherapy should be avoided in patients with moderate and severe hepatic impairment.
Croatian: Upotrebu lijeka ADCETRIS u kombinaciji s kemoterapijom treba izbjegavati u bolesnika s umjerenim i teškim oštećenjem funkcije jetre.
English: Study SGN35-005
Croatian: Ispitivanje SGN35-005
English: Co-administration of brentuximab vedotin did not affect the plasma exposure of AVD.
Croatian: Istodobna primjena brentuksimab vedotina nije imala utjecaja na plazmatsku izloženost AVD-u.
English: Tel. +358 20 746 5000 infoposti@takeda.com
Croatian: +358 20 746 5000 infoposti@takeda.com
English: Each pack of Adcetris consists of one vial.
Croatian: Jedno pakiranje lijeka Adcetris sadrži jednu bočicu.
English: Figure 2: Modified progression-free survival per IRF in patients with Stage IV disease (ADCETRIS + AVD vs. ABVD)
Croatian: Slika 2: Modificirano preživljavanje bez progresije bolesti prema IRF, kod bolesnika s bolesti u 4. stadiju (ADCETRIS + AVD u usporedbi s ABVD)
English: Peripheral sensory neuropathy, peripheral motor neuropathy
Croatian: Periferna senzorna neuropatija, periferna motorička neuropatija
English: Of the patients treated, 9 responding patients went on to receive an allogeneic stem cell transplant (SCT) and 9 responding patients went on to autologous SCT.
Croatian: Od liječenih bolesnika, 9 bolesnika s odgovorom nastavilo je s liječenjem do transplantacije alogenih matičnih stanica, a 9 bolesnika s odgovorom nastavilo je s liječenjem do transplantacije autolognih matičnih stanica.
English: Adcetris is used alone to treat classical Hodgkin lymphoma that has: - come back after or not responded to an infusion of your own healthy stem cells into your body (autologous stem cell transplant), or - come back after or never responded to at least two previous therapies, and where you cannot receive additional combination anti-cancer treatments or have an autologous stem cell transplant.
Croatian: Adcetris se primjenjuje kao samostalni lijek (monoterapija) za liječenje klasičnog Hodgkinovog limfoma koji se: - vratio nakon liječenja transplantacijom Vaših vlastitih matičnih stanica ili nije odgovorio na liječenje Vašim vlastitim zdravim matičnim stanicama (transplantacija autolognih matičnih stanica), ili - vratio ili nije odgovorio na najmanje dvije prethodne terapije i kad ne možete primiti dodatnu kombiniranu antitumorsku terapiju ili Vam se ne mogu transplantirati vlastite matične stanice.
English: How to store Adcetris
Croatian: Kako čuvati Adcetris
English: The efficacy and safety of ADCETRIS were evaluated in a randomised, open-label, 2-arm, multicenter trial in 1334 patients with previously untreated advanced HL in combination with chemotherapy (doxorubicin [A], vinblastine [V] and dacarbazine [D] [AVD]).
Croatian: Djelotvornost i sigurnost lijeka ADCETRIS ocijenjeni su u randomiziranom, otvorenom, multicentričnom ispitivanju s dvije skupine na 1334 bolesnika s prethodno neliječenim, uznapredovalim HL, u kombinaciji s kemoterapijom (doksorubicin [A], vinblastin [V] i dakarbazin [D] [AVD]).
English: Table 15: Sample calculations for patients receiving the recommended dose of 1.8 mg/kg of ADCETRIS for weights ranging from 60 kg to 120 kg
Croatian: Tablica 15: Primjeri izračuna za bolesnike koji primaju preporučenu dozu od 1,8 mg/kg lijeka ADCETRIS za tjelesne težine u rasponu od 60 kg do 120 kg
English: 13.2, NE
Croatian: 13,2, NP
English: Each vial contains a 10% overfill giving 55 mg of Adcetris per vial and a total reconstituted volume of 11 mL.
Croatian: Svaka bočica sadrži 10% suviška što daje 55 mg lijeka ADCETRIS po bočici i ukupni rekonstituirani volumen od 11 ml.
English: An excretion study was undertaken in patients who received a dose of 1.8 mg/kg of brentuximab vedotin.
Croatian: Ispitivanje izlučivanja provedeno je u bolesnika koji su primali dozu od 1,8 mg/kg brentuksimab vedotina.
English: Do not add other medicinal products to the prepared ADCETRIS infusion solution or intravenous infusion set.
Croatian: Nemojte dodavati druge lijekove pripremljenoj otopini za infuziju lijeka ADCETRIS ili u komplet za intravensku infuziju.
English: Some infections may be serious and can be due to viruses, bacteria, or other causes that may be life-threatening experience a whistling sound during breathing (wheezing)/difficulty breathing, hives, itching, or swelling (signs of an infusion reaction).
Croatian: Neke infekcije uzrokovane virusima, bakterijama ili drugim uzročnicima mogu biti ozbiljne i potencijalno smrtonosne - razvijete zvuk piskanja tijekom disanja (zviždanja)/otežano disanje, koprivnjaču, svrbež ili oticanje (znakovi reakcije na infuziju).
English: The median number of cycles was 7 (range, 2 to 37 cycles).
Croatian: Medijan broja ciklusa iznosio je 7 (raspon od 2 do 37 ciklusa).
English: Suggested evaluation of PML includes neurology consultation, gadolinium-enhanced magnetic resonance imaging of the brain and cerebrospinal fluid analysis for JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV.
Croatian: PML, potrebno je prekinuti liječenje lijekom ADCETRIS i započeti dijagnostičku obradu PML-a koja uključuje neurološki pregled, magnetsku rezonanciju mozga s gadolinijem, analizu cerebrospinalnog likvora na JCV DNK metodom lančane polimeraze (PCR) ili biopsiju mozga s dokazom JCV.
English: Stage II
Croatian: Stadij II
English: In the event of new or worsening GI symptoms, perform a prompt diagnostic evaluation and treat appropriately.
Croatian: U slučaju pojave novih ili pogoršanja gastrointestinalnih simptoma potrebne su žurna dijagnostička procjena i odgovarajuće liječenje.
English: Stage III
Croatian: Stadij III
English: In clinical trials treatment emergent neuropathy occurred in 59% of the population, peripheral motor neuropathy occurred in 14% of patients.
Croatian: U kliničkim ispitivanjima neuropatija se tijekom liječenja pojavila u 59% populacije, a periferna motorna neuropatija se pojavila u 14% bolesnika.
English: A. POTAMITIS MEDICARE LTD Tηλ: +357 22583333 info@potamitismedicare.com
Croatian: POTAMITIS MEDICARE LTD Tηλ: +357 22583333 info@potamitismedicare.com
English: 62 years (22-83)
Croatian: 62 godine (22-83)
English: The safety, pharmacokinetics and anti-tumour activity of ADCETRIS in 36 paediatric patients (7-17 years of age) with r/r HL and sALCL (children aged 7-11 years, n = 12 and adolescents aged 12 to 17 years, n = 24) were evaluated in a phase 1/2 open-label, single-agent, multicentre doseescalation study (C25002).
Croatian: Sigurnost, farmakokinetika i antitumorska aktivnost lijeka ADCETRIS procijenjene su u 36 pedijatrijskih bolesnika (u dobi od 7 do 17 godina) s r/r HL-om i sa sALCL-om (djeca u dobi od 7 do 11 godina, n=12 i adolescenti u dobi od 12 do 17 godina, n=24) u otvorenom, multicentričnom ispitivanju faze 1/2 u kojem se ispitivala monoterapija uz postupno povećanje doze (C25002).
English: Nausea, constipation, vomiting, diarrhoea, abdominal pain, stomatitis
Croatian: Mučnina, zatvor, povraćanje, proljev, bol u abdomenu, stomatitis
English: The 32 patients (53%) who did not receive subsequent SCT also received ADCETRIS for a median of 7 cycles (range, 1 to 16 cycles).
Croatian: Trideset dva bolesnika (53%) kojima nisu kasnije transplantirane matične stanice također je primilo medijan od 7 ciklusa lijeka ADCETRIS (u rasponu od 1 do 16 ciklusa).
English: At the time of the updated analysis (3 years of follow-up) for patients with 2 or more risk factors, the hazard ratio for PFS per IRF was 0.49 (95% CI [0.34, 0.71]) and the hazard ratio for PFS per investigator was 0.41 (95% CI [0.29, 0.58]) (see Figures 3 and 4).
Croatian: U vrijeme ažurirane analize (nakon 3 godine praćenja) za bolesnike s 2 ili više rizičnih čimbenika omjer hazarda za PFS po IRF-u bio je 0,49 (95% CI [0,34; 0,71]), a omjer hazarda za PFS po ispitivaču bio je 0,41 (95% CI [0,29; 0,58]) (vidjeti slike 3 i 4).
English: Of the 35 patients (33%) who had B symptoms at baseline, 27 patients (77%) experienced resolution of all B symptoms at a median time of 0.7 months from initiation of ADCETRIS.
Croatian: Od 35 bolesnika (33%) koji su imali B simptome na početku, u 27 bolesnika (77%) simptomi su se potpuno povukli nakon početka liječenja lijekom ADCETRIS, a medijan od početka liječenja iznosio je 0,7 mjeseci.
English: Represents pooling of preferred terms.
Croatian: Predstavlja preporučeni skupni izraz b.
English: ADCETRIS 50 mg powder for concentrate for solution for infusion.
Croatian: ADCETRIS 50 mg prašak za koncentrat za otopinu za infuziju.
English: PML has been reported in patients who received this treatment after receiving multiple prior chemotherapy regimens.
Croatian: PML je zabilježen u bolesnika koji su liječeni brentuksimab vedotinom nakon što su prethodno primili više kemoterapijskih protokola.
English: Serious infections such as pneumonia, staphylococcal bacteraemia, sepsis/septic shock (including fatal outcomes) and herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have been reported in patients treated with ADCETRIS.
Croatian: U bolesnika liječenih lijekom ADCETRIS zabilježene su ozbiljne infekcije kao što su pneumonija, stafilokokna bakterijemija, sepsa/septički šok (uključujući smrtne ishode), herpes zoster i citomegalovirus (CMV) (reaktivacija), te oportunističke infekcije kao što su pneumonija uzrokovana s Pneumocystis jirovecii i oralna kandidijaza.
English: Final Study Report by: Q1 2021
Croatian: Konačno izvješće o ispitivanju do: 1. kvartala 2021.
English: After multiple-dose, IV infusion of 1.2 mg/kg brentuximab vedotin every two weeks, steady-state trough concentrations of ADC and MMAE were achieved by Cycle 3.
Croatian: Nakon višestruke primjene intravenske infuzije od 1,2 mg/kg brentuksimab vedotina svaka dva tjedna, stanje dinamičke ravnoteže ADC i MMAE je postignuto do 3. ciklusa.
English: Adcetris contains the active substance brentuximab vedotin, an anti-cancer agent, which is made up of a monoclonal antibody linked to a substance intended to kill cancer cells.
Croatian: Adcetris sadrži djelatnu tvar brentuksimab vedotin, antitumorski lijek, koji je napravljen od monoklonskog protutijela vezanog s tvari koja uništava stanice raka.
English: Study C25001
Croatian: Ispitivanje C25001
English: In a phase 1 dose finding and safety study (SGN35-009), unacceptable pulmonary toxicity (including 2 fatal events) was noted in 11 of 25 patients (44%) treated with brentuximab vedotin plus ABVD.
Croatian: U ispitivanju faze 1 za određivanje doze i sigurnosti primjene (SGN35-009), u 11 od 25 bolesnika (44%) koji su primali brentuksimab vedotin istodobno s ABVD-om primijećena je neprihvatljiva plućna toksičnost (uključujući 2 smrtna ishoda).
English: Medicines of this type (monoclonal antibodies) can cause infusion reactions such as: a rash shortness of breath difficulty breathing cough a tight chest fever back pain chills headache feeling sick (nausea) or being sick (vomiting).
Croatian: Lijekovi ove vrste (monoklonska protutijela) mogu uzrokovati reakcije na infuziju kao što su: - osip - nedostatak zraka - otežano disanje - kašalj - stezanje u prsištu - vrućica - bol u leđima - zimica - glavobolja - mučnina ili povraćanje
English: Total ADCETRIS dose (mL) to be administered
Croatian: Ukupna doza lijeka ADCETRIS (ml) za primjenu
English: Management of TLS may include aggressive hydration, monitoring of renal function, correction of electrolyte abnormalities, anti-hyperuricaemic therapy, and supportive care.
Croatian: Liječenje sindroma lize tumora može uključivati adekvatnu hidraciju, praćenje bubrežne funkcije, korekciju poremećaja elektrolita, terapiju hiperuricemije i druge suportivne mjere liječenja.
English: If peripheral sensory or motor neuropathy emerges or worsens during treatment see Table 2 below for appropriate dosing recommendations (see section 4.4).
Croatian: Ako tijekom liječenja dođe do pogoršanja postojeće ili pojave novonastale periferne senzorne ili motoričke neuropatije, u tablici 2 su navedene preporuke za doziranje (vidjeti dio 4.4).
English: 33M (52%)/31F (48%)
Croatian: 33M (52%)/31Ž (48%)
English: Patients with hepatic impairment should be closely monitored for adverse events.
Croatian: Bolesnike s oštećenjem bubrega mora se pažljivo nadzirati radi štetnih događaja.
English: Infusion-related reactions
Croatian: Reakcije povezane s infuzijom
English: Median number of prior therapies (range)
Croatian: Medijan broja prethodnih liječenja (raspon)
English: Use of ADCETRIS in combination with chemotherapy should be avoided in patients with severe renal impairment.
Croatian: Upotrebu lijeka ADCETRIS u kombinaciji s kemoterapijom treba izbjegavati u bolesnika s teškim oštećenjem funkcije bubrega.
English: A pre-specified subgroup analysis of mPFS by disease stage showed that patients with Stage IV disease had a larger effect compared with the ITT population, with an unstratified hazard ratio of 0.71 (95% CI, 0.53; 0.96), compatible with a 29% reduction in the risk of modified PFS events for ADCETRIS+ AVD versus ABVD.
Croatian: Unaprijed specificirana analiza mPFS u podgrupama prema stadiju bolesti pokazala je da su bolesnici u 4. stadiju imali veći učinak u usporedbi sa ITT populacijom., sa nestratificiranim omjerom rizika 0,71 (95% CI, 0,53; 0,96), što odgovara 29% manjem riziku od modificiranih PFS događaja pri primjeni režima ADCETRIS + AVD naspram terapije sa ABVD.
English: A multiexponential decline in ADC serum concentrations was observed with a terminal half-life of approximately 4 to 6 days.
Croatian: Multieksponencijalni pad koncentracije ADC u serumu bio je opažen uz terminalni poluvijek od približno 4 do 6 dana.
English: John Cunningham virus (JCV) reactivation resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in ADCETRIS-treated patients.
Croatian: U bolesnika liječenih lijekom ADCETRIS može doći do reaktivacije virusa John Cunningham (JCV) i posljedične progresivne multifokalne leukoencefalopatije (PML) s mogućim smrtnim ishodom.
English: Adverse events led to treatment discontinuation in 24% of patients receiving ADCETRIS.
Croatian: Nuspojave su dovele do prekida liječenja u 24% bolesnika koji su primali ADCETRIS.
English: In the clinical trial of ADCETRIS as combination therapy, treatment emergent neuropathy occurred in 67% of the population; peripheral motor neuropathy occurred in 11% of patients.
Croatian: U kliničkim ispitivanjima lijeka ADCETRIS u kombiniranoj terapiji, neuropatija nastala tijekom liječenja pojavila se kod 67% bolesnika; periferna motorička neuropatija pojavila se kod 11% bolesnika.
English: In the study of ADCETRIS as combination therapy with AVD in 662 patients with previously untreated advanced HL (C25003), the most common adverse reactions (≥ 10%) were: neutropenia, nausea, constipation, vomiting, fatigue, peripheral sensory neuropathy, diarrhoea, pyrexia, alopecia, peripheral motor neuropathy, decreased weight, abdominal pain, anaemia, stomatitis, febrile neutropenia, bone pain, insomnia, decreased appetite, cough, headache, arthralgia, back pain, dyspnoea, myalgia, upper respiratory tract infection, alanine aminotransferase increased.
Croatian: Tijekom ispitivanja lijeka ADCETRIS u kombiniranoj terapiji s AVD-om u 662 bolesnika s neliječenim, uznapredovalim HL-om, (C25003), najčešće nuspojave (≥ 10%) bile su: neutropenija, mučnina, zatvor, povraćanje, umor, periferna senzorna neuropatija, proljev, pireksija, alopecija, periferna motorička neuropatija, gubitak tjelesne mase, bolovi u trbuhu, anemija, stomatitis, febrilna neutropenija, kostobolja, nesanica, smanjen apetit, kašalj, glavobolja, bolni zglobovi, bolovi u leđima, dispneja, mialgija, infekcija gornjih dišnih puteva, povećana ALT vrijednost.
English: The efficacy in elderly patients with Stage IV disease in the A + AVD arm (patients ≥ 60 years of age [n = 118] [HR = 0.80, 95% CI (0.42, 1.53)] and ≥ 65 years of age [n = 78] [HR = 0.78, 95% CI (0.36, 1.67)]) showed better benefit compared with elderly patients in ITT population.
Croatian: Djelotvornost u starijih bolesnika s bolesti u 4. Stadiju u A + AVD terapijskoj skupini (bolesnici ≥ 60 [n = 118] [HR = 0,80; 95% CI (0,42; 1,53)] i ≥ 65 [n = 78] [HR = 0,78, 95% CI (0,36; 1,67)]) ostvarili su veću korist u usporedbi sa starijim bolesnicima u ITT skupini.
English: Table 13: Summary of baseline patient and disease characteristics in the phase 3 CTCL Study (ITT Population)
Croatian: Tablica 13: Sažeti prikaz osobina bolesnika i značajki bolesti u ispitivanju CTCL-a faze 3 (populacija ITT)
English: A multiexponential decline in ADC serum concentrations was observed with a terminal half-life of approximately 4 to 5 days.
Croatian: Multieksponencijalni pad koncentracije ADC-a u serumu bio je opažen uz terminalni poluvijek od približno 4 do 5 dana.
English: The efficacy and safety of ADCETRIS were evaluated in a randomised, double-blind, placebo-controlled, 2-arm multicenter trial in 329 patients with HL at risk of relapse or progression following ASCT.
Croatian: Djelotvornost i sigurnost lijeka ADCETRIS ocijenjeni su u randomiziranom, dvostruko slijepom, placebom kontroliranom multicentričnom ispitivanju s 2 skupine u 329 bolesnika s HL-om s rizikom od relapsa ili progresije nakon ASCT-a.
English: 33 years (18-71)
Croatian: 33 godine (18-71)
English: Peripheral sensory neuropathy, peripheral motor neuropathy a,
Croatian: Periferna senzorna neuropatija, periferna motorička neuropatija a, omaglica
English: Of the 17 patients (29%) who had B symptoms at baseline, 14 patients (82%) experienced resolution of all B symptoms in a median time from initiation of ADCETRIS of 0.7 months.
Croatian: Od 17 bolesnika (29%) koji su imali B simptome na početku, svi B simptomi potpuno su se povukli u 14 bolesnika (82%), a medijan od početka liječenja lijekom ADCETRIS iznosio je 0,7 mjeseci.
English: An exploratory intra-patient analysis showed that approximately 64% of the HL patients treated with ADCETRIS as part of the SG035-0003 clinical study experienced an improvement in clinical benefit as measured by longer progression free survival (PFS) compared with their most recent prior line of therapy.
Croatian: Eksplorativna analiza u pojedinog bolesnika pokazala je da je približno 64% bolesnika s HL liječenih lijekom ADCETRIS u sklopu kliničkog ispitivanja SG035-0003 imalo kliničku korist, koja se mjerila duljim preživljenjem bez progresije bolesti (PFS) u usporedbi sa zadnjom linijom terapije koju su prethodno primili.
English: A fever with a low white blood cell count may be a sign of serious infection experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances (this may be a potentially life-threatening complication known as tumour lysis syndrome) experience flu-like symptoms followed by a painful red or purplish rash that spreads and blisters including extensive detachment of the skin that may be life-threatening (this may be a serious skin reaction known as Stevens-Johnson syndrome and toxic epidermal necrolysis) have new or worsening stomach pain, nausea, vomiting, constipation as these may be symptoms of a serious and potentially fatal stomach or intestinal complication (gastrointestinal complications)
Croatian: Vrućica s niskim brojem bijelih krvnih stanica može biti znak ozbiljne infekcije. - imate omaglicu, smanjeno mokrenje, smetenost, povraćanje, mučninu, oticanje, nedostatak zraka ili poremećaje srčanog ritma (to može biti potencijalno životno opasna komplikacija koja se zove sindrom lize tumora) - osjećate simptome nalik gripi praćene bolnim crvenim ili ljubičastim osipom koji se širi i mjehurima uključujući i opsežno odvajanje kože koje može biti opasno po život (to može biti ozbiljna kožna reakcija poznata kao Stevens-Johnsonov sindrom i toksična epidermalna nekroliza) - imate novonastalu ili pogoršanje boli u trbuhu, mučninu, povraćanje, zatvor, jer to mogu biti simptomi ozbiljne i potencijalno smrtonosne želučane ili crijevne komplikacije (komplikacije u probavnom sustavu)